{"id":"dopaminergic-medication","_chembl":{"chemblId":"CHEMBL2108889","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"explanation":"Dopaminergic medications can work through various mechanisms including dopamine receptor agonism, dopamine reuptake inhibition, or modulation of dopamine synthesis and metabolism. Without specific molecular target information, the precise mechanism of this investigational agent remains unclear.","oneSentence":"Affects dopamine neurotransmission through interaction with dopamine receptors or dopamine metabolism pathways."},"_scrapedAt":"2026-03-28T05:02:34.245Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123423,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"levodopa","brand":"Sinemet","company":null,"rationale":"Standard dopaminergic therapy for Parkinson's disease"},{"name":"pramipexole","brand":"Mirapex","company":null,"rationale":"Dopamine agonist used in Parkinson's and restless legs syndrome"},{"name":"ropinirole","brand":"Requip","company":null,"rationale":"Dopamine agonist for Parkinson's disease treatment"}],"description":"A dopaminergic medication in Phase 1 clinical development by Universidad Francisco de Vitoria. Dopaminergic drugs work by affecting dopamine neurotransmission in the brain and are typically investigated for neurological and psychiatric conditions where dopamine signaling plays a key role.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT03648905","phase":"","title":"Clinical Laboratory Evaluation of Chronic Autonomic Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2018-09-06","conditions":"Parkinson's Disease, Multiple System Atrophy, Autonomic Failure","enrollment":89},{"nctId":"NCT07492160","phase":"PHASE2","title":"Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","status":"RECRUITING","sponsor":"Maimonides Medical Center","startDate":"2026-03-16","conditions":"Pregnancy, Abortion","enrollment":348},{"nctId":"NCT03947216","phase":"PHASE2","title":"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-10-23","conditions":"Parkinson Disease","enrollment":117},{"nctId":"NCT07151378","phase":"PHASE3","title":"Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-10-27","conditions":"PARKINSON DISEASE (Disorder)","enrollment":150},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT06295952","phase":"PHASE2","title":"A Study of Pasireotide in People With Prolactinoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-27","conditions":"Prolactin-Producing Pituitary Tumor","enrollment":10},{"nctId":"NCT06618157","phase":"NA","title":"Connectomic Guided DBS for Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Duke University","startDate":"2026-02-16","conditions":"Parkinson Disease, Tremor, Dyskinesias","enrollment":20},{"nctId":"NCT07400731","phase":"NA","title":"Short and Long-term Responses of PD Symptoms to Earstim","status":"NOT_YET_RECRUITING","sponsor":"Stoparkinson Healthcare Systems LLC","startDate":"2026-02","conditions":"PARKINSON DISEASE (Disorder)","enrollment":90},{"nctId":"NCT07402928","phase":"","title":"Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease","status":"RECRUITING","sponsor":"Danish Research Centre for Magnetic Resonance","startDate":"2025-06-02","conditions":"Healthy, Parkinson, Medication Administration","enrollment":140},{"nctId":"NCT04469959","phase":"PHASE2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-15","conditions":"Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant","enrollment":100},{"nctId":"NCT07386080","phase":"PHASE4","title":"Carbergoline for Antipsychotic Induced Hyperprolactinemia.","status":"NOT_YET_RECRUITING","sponsor":"Zealand University Hospital","startDate":"2026-05-01","conditions":"Scizophrenia","enrollment":146},{"nctId":"NCT06075771","phase":"PHASE4","title":"Dopaminergic Therapy for Anhedonia - 2","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-11-21","conditions":"Anhedonia, Depression","enrollment":70},{"nctId":"NCT06484075","phase":"PHASE1, PHASE2","title":"Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2024-11-21","conditions":"Healthy Volunteers, Alcohol Use Disorder (AUD)","enrollment":180},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT06785298","phase":"PHASE2, PHASE3","title":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT03190954","phase":"EARLY_PHASE1","title":"Brain Dopaminergic Signaling in Opioid Use Disorders","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2017-08-17","conditions":"Normal Physiology, Opioid Use Disorders","enrollment":153},{"nctId":"NCT05022147","phase":"PHASE1","title":"Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"James Liao","startDate":"2021-10-04","conditions":"Parkinson Disease, Gait Disorders, Neurologic, Disease Progression","enrollment":12},{"nctId":"NCT01626885","phase":"PHASE2, PHASE3","title":"A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":42},{"nctId":"NCT01626859","phase":"PHASE2, PHASE3","title":"A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":38},{"nctId":"NCT06498349","phase":"NA","title":"Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl","status":"RECRUITING","sponsor":"University of Kiel","startDate":"2024-09-05","conditions":"Parkinson Disease, Impulse Control Disorders","enrollment":60},{"nctId":"NCT01626872","phase":"PHASE2, PHASE3","title":"Long-Term Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-09","conditions":"Schizophrenia","enrollment":254},{"nctId":"NCT01625897","phase":"PHASE2, PHASE3","title":"A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":125},{"nctId":"NCT01625000","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":512},{"nctId":"NCT07297368","phase":"NA","title":"Enhanced Tai Chi for Parkinson's Disease (Enhanced Tai Chi PD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2024-05-01","conditions":"Parkinson Disease (PD)","enrollment":30},{"nctId":"NCT06587217","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-10-29","conditions":"Parkinsonian Signs in Older Persons","enrollment":5},{"nctId":"NCT07229664","phase":"PHASE2, PHASE3","title":"Vinpocetine in Patients With Parkinsonian Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-10","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT07273526","phase":"NA","title":"Adrenaline V/s Dopamine in Fuid Refractory Septic Shock","status":"RECRUITING","sponsor":"Laiba Qamar","startDate":"2025-06-01","conditions":"Fluid Refractory Septic Shock, Septic Shock","enrollment":90},{"nctId":"NCT07267065","phase":"PHASE1","title":"AAV2-hAADC for Parkinson's Disease (PDCS-01)","status":"NOT_YET_RECRUITING","sponsor":"Krzysztof Bankiewicz","startDate":"2026-02-01","conditions":"Parkinson's Disease (PD), Early Onset Parkinson Disease","enrollment":9},{"nctId":"NCT07257393","phase":"","title":"Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health","status":"NOT_YET_RECRUITING","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2025-12-01","conditions":"Idiopathic Parkinsonism","enrollment":100},{"nctId":"NCT04653688","phase":"NA","title":"Markers of Disease Progression and Gait Within the Parkinsonian Population","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2020-12-22","conditions":"Parkinson Disease","enrollment":83},{"nctId":"NCT04228523","phase":"NA","title":"Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2020-02-24","conditions":"Parkinson Disease","enrollment":24},{"nctId":"NCT07244640","phase":"","title":"Non-Invasive Fundus Retinal Detection Technology for Early Diagnosis of Parkinson's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-11","conditions":"Parkinson's Disease (PD)","enrollment":200},{"nctId":"NCT07238465","phase":"PHASE3","title":"Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12","conditions":"Down Syndrome, Autonomic Dysfunction","enrollment":200},{"nctId":"NCT07072910","phase":"PHASE2","title":"Cabergoline for Episodic Migraine","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-12","conditions":"Migraine","enrollment":150},{"nctId":"NCT03161652","phase":"PHASE2","title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","status":"RECRUITING","sponsor":"Carmen Clapp","startDate":"2017-05-24","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":120},{"nctId":"NCT04317807","phase":"PHASE2","title":"R33: Levetiracetam in Early Psychosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-27","conditions":"Early Psychosis","enrollment":65},{"nctId":"NCT06179108","phase":"PHASE2","title":"Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"LB Pharmaceuticals Inc.","startDate":"2023-11-29","conditions":"Schizophrenia","enrollment":359},{"nctId":"NCT07045935","phase":"PHASE4","title":"Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-09-16","conditions":"Prolactinoma","enrollment":60},{"nctId":"NCT02260570","phase":"EARLY_PHASE1","title":"Remediation of Impaired Self-Regulation in Patients With Mild TBI","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-08-01","conditions":"Mild Traumatic Brain Injury","enrollment":55},{"nctId":"NCT05103618","phase":"PHASE2","title":"Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA","status":"WITHDRAWN","sponsor":"Andrew Newberg","startDate":"2021-07-08","conditions":"Parkinson Disease, Idiopathic Parkinson Disease","enrollment":""},{"nctId":"NCT07173738","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2018-06-11","conditions":"Pulmonary Arterial Hypertension","enrollment":44},{"nctId":"NCT07001150","phase":"PHASE2","title":"Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-05-10","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT06740812","phase":"PHASE4","title":"Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Nausea and Vomiting, Nausea, Vomiting","enrollment":212},{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT02169310","phase":"PHASE1","title":"Neural Basis of Decision-Making Deficits in Traumatic Brain Injury","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2014-11-18","conditions":"Traumatic Brain Injury","enrollment":45},{"nctId":"NCT05116813","phase":"PHASE2, PHASE3","title":"Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy","status":"TERMINATED","sponsor":"Addex Pharma S.A.","startDate":"2021-10-25","conditions":"Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias","enrollment":17},{"nctId":"NCT04459052","phase":"PHASE2","title":"FDOPA PET and Nutritional Support in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2020-04-30","conditions":"Parkinson Disease, Idiopathic Parkinson Disease","enrollment":50},{"nctId":"NCT05636852","phase":"PHASE2","title":"Altropane Dose for Imaging Patients With Suspected Parkinson's Disease","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2023-04-24","conditions":"Parkinson Disease, Movement Disorders","enrollment":15},{"nctId":"NCT06333990","phase":"PHASE3","title":"Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)","status":"RECRUITING","sponsor":"Foundation for Advancing Veterans' Health Research","startDate":"2024-07-09","conditions":"Mild Traumatic Brain Injury","enrollment":146},{"nctId":"NCT06155812","phase":"PHASE2, PHASE3","title":"Multimodal Vasopressor Strategy in Septic Shock","status":"RECRUITING","sponsor":"University Medical Centre Maribor","startDate":"2023-12-23","conditions":"Shock, Septic","enrollment":80},{"nctId":"NCT06219915","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-03-15","conditions":"Parkinsonian Signs in Older Persons","enrollment":13},{"nctId":"NCT02288962","phase":"PHASE3","title":"Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2014-11","conditions":"Pituitary Neoplasms, Adenoma","enrollment":60},{"nctId":"NCT06729658","phase":"EARLY_PHASE1","title":"Dopamine and Brain Computer Interface","status":"COMPLETED","sponsor":"Max Planck Institute for Human Cognitive and Brain Sciences","startDate":"2017-10-01","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT06808932","phase":"PHASE1","title":"VK4-116 Phase I Study With Food-Effect","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2025-11-01","conditions":"Opioid Dependence, Opioid Use Disorder (OUD)","enrollment":48},{"nctId":"NCT05838430","phase":"PHASE4","title":"Solriamfetol and CBT-I in Patients With Insomnia Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-31","conditions":"Insomnia","enrollment":60},{"nctId":"NCT06369623","phase":"NA","title":"Monetary Incentive Delay Task for Probing Reward-related Neural Processes","status":"RECRUITING","sponsor":"Stony Brook University","startDate":"2024-04-06","conditions":"Adolescent Development","enrollment":300},{"nctId":"NCT06967831","phase":"","title":"Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2020-03-01","conditions":"Leigh Syndrome (Maternally Inherited, MILS), Leigh Syndrome (AR, AD, XR)","enrollment":80},{"nctId":"NCT06951334","phase":"NA","title":"Clinical Trial of Vildagliptin in Early Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-06-01","conditions":"Parkinson's Disease","enrollment":66},{"nctId":"NCT06936254","phase":"","title":"One-Year Effect on Levodopa Equivalent Daily Dose of Thalamic VIM Nucleus Stimulation Compared to Subthalamic Nucleus Stimulation in Patients With Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-04-30","conditions":"Parkinson Disease (PD), Deep Brain Stimulation","enrollment":94},{"nctId":"NCT06269146","phase":"PHASE2","title":"Pramipexole to Enhance Social Connections","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-05-13","conditions":"Anxiety Disorders, Anxiety, Depression","enrollment":108},{"nctId":"NCT05119075","phase":"NA","title":"Psychological Effects of Levodopa in Parkinson's Disease","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-11-10","conditions":"Parkinson Disease","enrollment":23},{"nctId":"NCT04128683","phase":"EARLY_PHASE1","title":"Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-10-20","conditions":"Anorexia Nervosa","enrollment":31},{"nctId":"NCT05182892","phase":"NA","title":"REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-12-13","conditions":"Parkinson Disease","enrollment":45},{"nctId":"NCT05765110","phase":"NA","title":"SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-01-03","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT03911726","phase":"NA","title":"Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2020-08-01","conditions":"Schizophrenia","enrollment":140},{"nctId":"NCT05641623","phase":"PHASE2","title":"OSU6162 as add-on in SSRI/SNRI-resistant Depression","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2022-04-21","conditions":"Depression, Depressive Disorder, Treatment-Resistant, Depressive Disorder","enrollment":180},{"nctId":"NCT05369533","phase":"PHASE1, PHASE2","title":"Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-08-01","conditions":"Stroke","enrollment":25},{"nctId":"NCT06344026","phase":"PHASE1","title":"Phase 1/2a Study of ANPD001 in Parkinson Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Aspen Neuroscience","startDate":"2024-01-23","conditions":"Parkinson Disease","enrollment":9},{"nctId":"NCT05890768","phase":"PHASE4","title":"Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2023-05-11","conditions":"Psychosis","enrollment":""},{"nctId":"NCT06497660","phase":"PHASE4","title":"Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-08-01","conditions":"Breast Cancer, Neoadjuvant Chemotherapy, Perioperative Period","enrollment":496},{"nctId":"NCT05140148","phase":"PHASE2","title":"Promoting Recovery After STroke With Amantadine","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-02-01","conditions":"Stroke, Ischemic, Stroke Hemorrhagic","enrollment":60},{"nctId":"NCT06586320","phase":"NA","title":"Quantification of Parkinson's Disease Patients As a Biomarker for Classification, Prediction and Response to Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"Stardots AB","startDate":"2025-02-06","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT06832358","phase":"NA","title":"Positive Psychological Intervention for Parkinson's Disease Patients","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-02-01","conditions":"Parkinson","enrollment":60},{"nctId":"NCT06688357","phase":"NA","title":"Revitalize Cognition: Near Infrared Stimulation in Parkinson Patients","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-06-26","conditions":"Parkinson Disease","enrollment":23},{"nctId":"NCT06784570","phase":"PHASE2","title":"Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2021-01-01","conditions":"Cardiac Surgery, Low Ejection Fraction","enrollment":240},{"nctId":"NCT05285683","phase":"PHASE2","title":"The Role of Brain Dopamine in Chronic Pain","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2024-01-31","conditions":"Chronic Pain","enrollment":10},{"nctId":"NCT06754553","phase":"","title":"Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-02","conditions":"Parkinson Disease","enrollment":100},{"nctId":"NCT04038957","phase":"PHASE1","title":"A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-08-07","conditions":"Schizophrenia","enrollment":22},{"nctId":"NCT05184335","phase":"PHASE3","title":"Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia","status":"RECRUITING","sponsor":"Reviva Pharmaceuticals","startDate":"2022-01-24","conditions":"Schizophrenia","enrollment":690},{"nctId":"NCT04723147","phase":"PHASE4","title":"DTA (Dopaminergic Therapy for Anhedonia) Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-01-29","conditions":"Depression, Anhedonia","enrollment":19},{"nctId":"NCT02817698","phase":"EARLY_PHASE1","title":"Imaging the Neurochemistry of Drug Addiction With PET","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-11-29","conditions":"Smoking, Cannabis","enrollment":25},{"nctId":"NCT05585827","phase":"NA","title":"Online Cognitive Behavioral Therapy for Depressive Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Helse Stavanger HF","startDate":"2022-12-07","conditions":"Parkinson Disease, Depressive Symptoms, Anxiety","enrollment":11},{"nctId":"NCT04807517","phase":"PHASE4","title":"Buspirone Treatment of Anxiety in Williams Syndrome","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-08-01","conditions":"Williams Syndrome, Anxiety","enrollment":20},{"nctId":"NCT06675851","phase":"PHASE4","title":"Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2022-12-01","conditions":"Major Depressive Disorder (MDD)","enrollment":120},{"nctId":"NCT04369573","phase":"PHASE4","title":"Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock","status":"TERMINATED","sponsor":"Niguarda Hospital","startDate":"2020-05-04","conditions":"Cardiogenic Shock","enrollment":100},{"nctId":"NCT00581009","phase":"PHASE1, PHASE2","title":"The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2001-05-30","conditions":"Major Depressive Disorder, Bipolar Disorder","enrollment":49},{"nctId":"NCT06551727","phase":"NA","title":"Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke","status":"ENROLLING_BY_INVITATION","sponsor":"Ruijin Hospital","startDate":"2024-08-15","conditions":"Stroke, Ischemic","enrollment":70},{"nctId":"NCT05822258","phase":"NA","title":"DetectFoG : Detection of Gait Freezing Episodes in Parkinsonian Patients Using Inertial Measurement Units","status":"RECRUITING","sponsor":"Rennes University Hospital","startDate":"2024-01-08","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT05001217","phase":"PHASE2, PHASE3","title":"Chinese Herbal Medicine Treatment as Adjunct Therapy for Parkinson's Disease","status":"COMPLETED","sponsor":"Hong Kong Baptist University","startDate":"2022-01-01","conditions":"Parkinson Disease","enrollment":160},{"nctId":"NCT05243251","phase":"PHASE3","title":"Olanzapine Anorexia Cachexia","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-12-25","conditions":"Anorexia","enrollment":164},{"nctId":"NCT06583005","phase":"NA","title":"Vibrotactile Coordinated Reset for Parkinsons Patients Who Are on Dopaminergic Medication","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-02-15","conditions":"Parkinson Disease, Idiopathic","enrollment":20},{"nctId":"NCT00580814","phase":"NA","title":"Brain Dopamine Function in Adults With ADHD","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2006-02","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":75},{"nctId":"NCT06481800","phase":"NA","title":"PMR Versus MLD on RLS and Sleep Quality in Hemodialysis Patients","status":"COMPLETED","sponsor":"MTI University","startDate":"2024-04-15","conditions":"Hemodialysis Complication","enrollment":120},{"nctId":"NCT06468371","phase":"NA","title":"Exercise Training Versus Ropinirole in Treating Restless Legs Syndrome Among Hemodialysis Patients","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2022-01-02","conditions":"Hemodialysis, Restless Legs Syndrome, ESRD (End Stage Renal Disease)","enrollment":84},{"nctId":"NCT01244815","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-16","conditions":"Bipolar Disorder, Pediatric","enrollment":404},{"nctId":"NCT06413420","phase":"","title":"SUNOSI® (Solriamfetol) Pregnancy Registry","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-07-31","conditions":"Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring","enrollment":1731},{"nctId":"NCT06365515","phase":"NA","title":"Dopamine, Reward Learning and Sex Hormones","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2024-05","conditions":"Hormonal Changes, Menstrual Cycle","enrollment":90},{"nctId":"NCT03059563","phase":"PHASE1","title":"Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2018-01-11","conditions":"Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse","enrollment":62},{"nctId":"NCT06214377","phase":"NA","title":"Transcranial Direct Current Stimulation for Treating Parkinson´s Disease-related Pain in OFF State","status":"COMPLETED","sponsor":"Universidad Francisco de Vitoria","startDate":"2023-07-01","conditions":"Parkinson Disease, Pain","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1162,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Dopaminergic medication","genericName":"Dopaminergic medication","companyName":"Universidad Francisco de Vitoria","companyId":"universidad-francisco-de-vitoria","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dopaminergic medications are used to treat conditions such as Parkinson Disease, Idiopathic Parkinson Disease, and Schizophrenia, as indicated by ClinicalTrials.gov. The exact mechanism of action of dopaminergic medications is unknown, according to ChEMBL.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}